文献速递肿瘤 PET/CT

[18F]DCFPyL PET/CT在前列腺切除术后复发前列腺癌检测与定位中的应用:包括PSA<0.5 ng/mL的低PSA组

[18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-01-05

这项回顾性多中心分析评估了[18F]DCFPyL PSMA PET/CT在根治性前列腺切除术后复发前列腺癌检测和定位中的表现,特别关注PSA<0.5 ng/mL的低PSA组。222例患者按PSA分为五组,总体异常摄取提示复发的前列腺癌检出率为69.8%,低PSA亚组(<0.5 ng/mL)检出率相似。结论认为即使低PSA水平检出率也高,指南采用 rigid PSA阈值可能延误部分患者治疗。

要点

  • 222例前列腺切除术后复发患者中,155例(69.8%)[18F]DCFPyL PET/CT有异常摄取提示复发。
  • PSA≥2 ng/mL组检出率91.7%,PSA 0.2-0.49 ng/mL组58.7%,PSA≤0.2 ng/mL组63.6%。
  • PSA<0.5 ng/mL组中47.6%可检出病灶,其中71.4%局限于盆腔。

核心结论

  • [18F]DCFPyL PET/CT在根治性前列腺切除术后复发检测中检出率高,即使在低PSA水平也如此,PSA<0.5 ng/mL亚组间检出水平相似。
  • 指南若采用 rigid PSA阈值来设定PSMA PET/CT资助资格,可能导致大量低于阈值的患者治疗延迟或不适当。

研究设计与样本

  • 回顾性多中心分析,纳入澳大利亚和新西兰中心的联合PSMA数据库患者。
  • 共222例根治性前列腺切除术后复发患者,按PSA(ng/mL)分为五组:0-0.19、0.2-0.49、0.5-0.99、1-1.99和≥2。
  • 记录[18F]DCFPyL PET/CT检测的病灶为局部复发、区域淋巴结和转移。

主要发现

  • 222例中155例(69.8%)有异常摄取提示复发前列腺癌。
  • 各PSA组检出率:≥2 ng/mL组91.7%(44/48),1-1.99 ng/mL组82.1%(23/28),0.5-0.99 ng/mL组62.8%(27/43),0.2-0.49 ng/mL组58.7%(54/92),≤0.2 ng/mL组63.6%(7/11)。
  • PSA<0.5 ng/mL组中47.6%(49/103)可检出病灶;其中71.4%(35/49)病变局限于盆腔,22.4%(11/49)为前列腺床复发,49.0%(24/49)为盆腔淋巴结,28.6%(14/49)为盆腔外病变。

临床怎么用

  • 对于根治性前列腺切除术后生化复发患者,即使PSA<0.5 ng/mL,也可考虑行[18F]DCFPyL PET/CT以检测和定位复发灶。
  • 制定PSMA PET/CT指南和资助路径时,不宜仅采用 rigid PSA阈值,以免遗漏低PSA但可检出病灶的患者。

局限性

  • 回顾性多中心设计,可能存在选择偏倚。
  • 低PSA亚组样本量较小(如PSA≤0.2 ng/mL组仅11例),结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The primary aim of this retrospective multicenter analysis was to assess the performance of PSMA PET/CT using [18F]DCFPyL in the detection and localization of recurrent prostate cancer post radical prostatectomy (RP). Particular reference is given to low PSA groups < 0.5 ng/mL to aid discussion around the inclusion of this group in PSMA guidelines and funding pathways. METHODS: Retrospective analysis of combined PSMA database patients from centers in Australia and New Zealand. Two hundred twenty-two patients presenting with recurrence post RP were stratified into five PSA groups (ng/mL): 0-0.19, 0.2-0.49, 0.5-0.99, 1-1.99, and ≥ 2. Lesions detected by [18F]DCFPyL PET/CT were recorded as local recurrence, locoregional nodes, and metastases. RESULTS: Of 222 patients, 155 (69.8%) had evidence of abnormal uptake suggestive of recurrent prostate cancer. The detection efficacies for [18F]DCFPyL PET/CT were 91.7% (44/48) for PSA levels ≥ 2 ng/mL, 82.1% (23/28) for PSA levels 1-1.99 ng/mL, 62.8% (27/43) for PSA levels 0.5-0.99 ng/mL, 58.7% (54/92) for PSA levels 0.2-0.49 ng/mL, and 63.6% (7/11) for PSA levels ≤ 0.2 ng/mL. In those with PSA < 0.5 ng/mL, 47.6% (49/103) had detectable lesions, 71.4% (35/49) had disease confined to the pelvis, 22.4% (11/49) had prostate bed recurrence, 49.0% (24/49) had pelvic lymph nodes, and 28.6% (14/49) had extra pelvic disease. CONCLUSION: [18F]DCFPyL PET/CT has a high detection rate in recurrence following RP even at low PSA levels with similar detection levels in the PSA subgroups < 0.5 ng/mL. Employing rigid PSA thresholds when constructing guidelines for PSMA PET/CT funding eligibility may result in a significant number of patients below such thresholds having delayed or inappropriate treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Perry E, Talwar A, Taubman K, et al. [18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL. Eur J Nucl Med Mol Imaging. 2021. PMID: 33399941. doi:10.1007/s00259-020-05143-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。